Note：This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

October 27, 2025

To the Public

Company Name: EM SYSTEMS CO., LTD.
Representative: Hiromasa Kunimitsu, Representative Director and President
Code No: 4820
Tokyo Stock Exchange Prime Market
Inquiries: Daigo Kobayashi, Senior Executive Officer, General Manager of Corporate Strategic Division
Tel: +81-(0)6-6397-1888

Notice of Revisions to the Forecast of Consolidated Financial Results and Dividends for the Fiscal Year Ending December 31, 2025

We have revised our consolidated earnings forecasts for the fiscal year ending December 31, 2025 and our dividend forecasts for the fiscal year ending December 31, 2025, in light of recent performance trends and other factors.

Ⅰ. Consolidated Earnings Forecast

(1) Revisions to the consolidated earnings forecasts for the fiscal year ending December 31, 2025 (January 1, 2025 to December 31, 2025)

	Net sales	Operating income	Ordinary income	Attributable to owners of parent net income	Net income per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A)	21,740	2,522	3,154	1,854	26.82
Revised forecast (B)	23,479	3,627	4,389	2,691	38.90
Change (B-A)	1,739	1,105	1,235	836	-
Change (%)	8.0	43.8	39.2	45.1	-
(Reference) Previous fiscal year results Consolidated cumulative accounting period	24,837	4,464	5,184	2,425	34.54

(2) Reasons for the revision

In our group, we are continuing our efforts to realize high-quality medical care by promoting healthcare dx and innovation. In line with the expansion of the scope of Online eligibility verification system operation under the Medical dx Reiwa Vision 2030 and the promotion of Electronic Prescriptions, we are responding to the medical assistance of the Online eligibility verification system and gradually expanding the installation of Electronic Prescriptions.

During the first three quarters of the fiscal year under review, the Company's response to healthcare dx, including the introduction of Electronic Prescriptions and the provision of healthcare assistance under its Online eligibility verification system, exceeded initial expectations and progressed steadily, which is expected to boost earnings.

Accordingly, we have decided to revise the net sales and profit at each stage of the forecast of consolidated financial results for the fiscal year ending December 31, 2025, which was announced on February 14, 2025, as described above.

The full-year results of operations are also expected to be affected by the conversion of Precal Co., Ltd. into a subsidiary. The Company also plans to disclose its financial results for the third quarter of the fiscal year ending December 2025 on November 14, 2025.

Ⅱ. Dividend Forecast

(1) Revision of year-end dividend forecast

Dividends per share			
Record date	End of 2nd quarter	End of term	Annual
Previous forecast (out February 14, 2025)	-	18.00 yen	35.00 yen
Revised forecast	-	22.00 yen	39.00 yen
Results for the fiscal year under review	17.00 yen	-	-
Results for the Fiscal Year Ended December 31, 2024	9.00 yen	26.00 yen	35.00 yen

(2) Details of modification

Based on our policy of returning profits to shareholders under the [New Medium-Term Management Plan], we have upwardly revised our year-end dividend forecast, as described above, to 22 yen, an increase of 4 yen from the previous forecast.

The annual dividend has been revised to 39 yen, including the interim dividend of 17 yen per share.

(N.B.) The above forecasts are based on information currently available to us, and actual results may differ from the forecasts due to various factors in the future.

End